Share the post "Aurobindo Pharma announced Financial Results Q1 2024"
Highlights
- The presented financial data is Consolidated to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 10.46 % in the past year, decrease in net sales/revenue by -0.17 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 374.3 %. Marginal increase in other income during this quarter, up by 1535.31%.
- Profit over the Year and quarter: Significant improvement in profitability for Aurobindo Pharma Ltd.. Notable increase of 61.17 % in net profit Year to Year, Aurobindo Pharma Ltd.’s profitability increased by 1.2 % in this quarter.
- EPS over the Year and quarter: EPS increased by 61.09 % Year to Year. EPS increased by 1.16 % in previous quarter. Positive impact on shareholders.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 6850.52 Cr | Rs. 7580.15 Cr | Rs. 7567.02 Cr | -0.17 % | + 10.46 % |
Expenses | Rs. 5701.96 Cr | Rs. 5920 Cr | Rs. 5948.84 Cr | + 0.49 % | + 4.33 % |
Operating Profit | Rs. 1148.56 Cr | Rs. 1660.15 Cr | Rs. 1618.18 Cr | -2.53 % | + 40.89 % |
OPM % | 16.77 % | 21.9 % | 21.38 % | -0.52 % | + 4.61 % |
Other Income | Rs. 46.58 Cr | Rs. 13.51 Cr | Rs. 220.93 Cr | + 1535.31 % | + 374.3 % |
Interest | Rs. 56.55 Cr | Rs. 89.43 Cr | Rs. 111.04 Cr | + 24.16 % | + 96.36 % |
Depreciation | Rs. 326.56 Cr | Rs. 354.33 Cr | Rs. 404.18 Cr | + 14.07 % | + 23.77 % |
Profit before tax | Rs. 812.03 Cr | Rs. 1229.9 Cr | Rs. 1323.89 Cr | + 7.64 % | + 63.03 % |
Tax % | 29.74 % | 25.96 % | 30.61 % | + 4.65 % | + 0.87 % |
Net Profit | Rs. 569.71 Cr | Rs. 907.35 Cr | Rs. 918.22 Cr | + 1.2 % | + 61.17 % |
EPS in Rs | Rs. 9.74 | Rs. 15.51 | Rs. 15.69 | + 1.16 % | + 61.09 % |
Today, we’re looking at Aurobindo Pharma Ltd.’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 10.46 %. However, it did see a marginal slip of -0.17 % from the previous quarter. Expenses ticked up slightly by 0.49 % quarter-on-quarter, aligning with the annual rise of 4.33 %. Operating profit, while up 40.89 % compared to last year, faced a quarter-on-quarter dip of -2.53 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.61 %, but a shrinkage of -0.52 % sequentially. Other income rose by 1535.31 % compared to the last quarter, despite an annual growth of 374.3 %. Interest expenses surged remarkably by 24.16 % from the previous quarter, yet the year-over-year increase remains at a moderate 96.36 %. Depreciation costs climbed by 14.07 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 23.77 %. Profit before tax grew annually by 63.03 % but saw an increase from the preceding quarter by 7.64 %.
Tax expenses as a percentage of profits increased slightly by 0.87 % compared to last year, with a more notable quarter-on-quarter increase of 4.65 %. Net profit rose by 61.17 % year-on-year but experienced a 1.2 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 61.09 % but a quarterly rise of 1.16 %. In summary, Aurobindo Pharma Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 6850.52 Cr | Rs. 7580.15 Cr | Rs. 7567.02 Cr | -0.17 % | + 10.46 % |
Expenses | Rs. 5701.96 Cr | Rs. 5920 Cr | Rs. 5948.84 Cr | + 0.49 % | + 4.33 % |
Operating Profit | Rs. 1148.56 Cr | Rs. 1660.15 Cr | Rs. 1618.18 Cr | -2.53 % | + 40.89 % |
Net Profit | Rs. 569.71 Cr | Rs. 907.35 Cr | Rs. 918.22 Cr | + 1.2 % | + 61.17 % |
EPS in Rs | Rs. 9.74 | Rs. 15.51 | Rs. 15.69 | + 1.16 % | + 61.09 % |
In reviewing Aurobindo Pharma Ltd.’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.46 % year-on-year growth, although there was a slight dip of -0.17 % from the previous quarter. Expenses rose by 4.33 % compared to the previous year, with a 0.49 % increase quarter-on-quarter. Operating Profit surged by 40.89 % annually, and saw a -2.53 % decrease from the last quarter.
Net Profit showed yearly increase of 61.17 %, and experienced a 1.2 % increase from the previous quarter. Earnings Per Share (EPS) rose by 61.09 % annually, however rose by 1.16 % compared to the last quarter. In essence, while Aurobindo Pharma Ltd. exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.